Human leukocyte antigen class I and II peptide-binding grooves (HLA-I/II grooves)

The Human Leukocyte Antigen (HLA) class I and II peptide-binding grooves are specialized structural domains on MHC molecules that present antigens to the immune system. These grooves are formed by two alpha-helices resting on a floor of beta-strands, creating a pocket that binds short peptide fragments (Janeway's Immunobiology, 9th Ed). Class I grooves present endogenous peptides to CD8+ T cells, while Class II grooves present exogenous peptides to CD4+ T cells, facilitating the recognition of pathogens and tumors (Murphy & Weaver, 2016). The extreme polymorphism of these grooves across the human population determines individual immune repertoires and susceptibility to various diseases (Rock et al., Nature Reviews Immunology, 2016). In clinical pharmacology, these grooves are the site of interaction for several drugs that cause severe hypersensitivity reactions, such as abacavir and carbamazepine. These drugs can bind within the groove and alter the repertoire of presented self-peptides, leading to an inappropriate T-cell attack on healthy tissues (Illing et al., Nature, 2012). Additionally, the grooves are the primary target for peptide-based vaccines and neoantigen therapies designed to elicit specific anti-tumor immune responses. Understanding the structural biology of these grooves is essential for predicting adverse drug reactions and developing personalized immunotherapies.

Other names

MHC peptide-binding cleftHLA binding pocketsMajor Histocompatibility Complex peptide-binding groovesHLA-I and HLA-II grooves

Drugs or peptides bind within the HLA groove to either present specific antigens to T-cells or alter the repertoire of self-peptides presented, potentially triggering an immune response (Illing et al., Nature, 2012). Some drugs may also interact via the pharmacological interaction (p-i) mechanism, binding non-covalently to the HLA-peptide-TCR complex.